INSM - インスメッド （Insmed Inc.）

https://www.investing.com/news/pro/insmed-receives-investment-bank-analyst-rating-update-3062791

BRIDGEWATER, N.J., April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2023 financial results on…

Topline Data Remains on Track to be Reported in Q2 of 2024 More than 1,700 Adult Patients Enrolled in Global, Registrational Study of First-in-Class Treatment Candidate BRIDGEWATER, N.J., March 31, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical…

NEWARK, DE / ACCESSWIRE / March 15, 2023 / A report published by Future Market Insights predicts that the Chronic Pulmonary Hypertension Treatment Market will reach a valuation of US$ 7 billion in 2023 and is expected to accumulate a market value of US$ 11.4 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market is expected to witness significant growth in the coming years, driven by the increasing prevalence of pulmonary hypertension and the growing availability of effective treatment options. Pulmonary hypertension is a condition in which the blood pressure in the pulmonary artery, which carries blood from the heart to the lungs, becomes abnormally high. This can cause the right side of the heart to work harder, leading to heart failure if left untreated. Pulmonary hypertension can be caused by a variety of factors, including genetics, heart and lung disease, and exposure to certain drugs or toxins. Request a Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16779 One of the key drivers of the chronic pulmonary hypertension treatment market is the increasing prevalence of the disease.

The share price of Insmed Incorporated (NASDAQ:INSM) fell to $19.61 per share on Wednesday from $19.79. While Insmed Incorporated has underperformed by -0.91%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INSM fell by -15.33%, with highs and lows ranging from $28.94 to $16.41, whereas the […]

Insmed Incorporated (NASDAQ:INSM) price closed lower on Tuesday, May 24, dropping -4.15% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $20.01, with intraday deals fluctuated between $19.01 and $19.71. The … How Is Insmed Incorporated (NASDAQ: INSM) Doing? Read More »

Insmed <> is trading higher after the company''s director Melvin Sharoky bought 20,000 shares of the stock for an average price of $17.2 per shareThe total value adds up…

Insmed Inc. (NASDAQ:NASDAQ:INSM) Q1 2022 Results Conference Call May 05, 2022 08:30 AM ET Company Participants Eleanor Barisser - IR Will Lewis - Chairman, CEO Sara Bonstein - CFO…

Insmed (NASDAQ: INSM ) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Insmed beat estimated earnings by 9.09%, reporting an EPS of $-0.8 versus an … Full story available on Benzinga.com

Insmed press release (INSM): Q1 GAAP EPS of -$0.80 beats by $0.10.Revenue of $53.1M (+32.1% Y/Y) misses by $0.26M.

Insmed press release (INSM): Q4 GAAP EPS of -$0.95 misses by $0.05.Revenue of $56.12M (+35.5% Y/Y) beats by $5.28M.The company expects full-year 2022 revenues for ARIKAYCE to…

BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31,…

Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.